Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
for
Carcinoma of Unknown Primary,
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center
Sex: All
Age: 18+
Code: NCT03010150
Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
for
Clear Cell Renal Cell Carcinoma,
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center
Sex: All
Age: 18+
Code: NCT06447103
Phase2, Recruiting
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
for
Breast Cancer, Locally Advanced Breast Cancer,
Location: Chapel Hill NC
Sponsor: UNC Lineberger Comprehensive Cancer Center
Sex: Female
Age: 18+
Code: NCT06727773
Phase2, Recruiting
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
for
Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8,
Location: Alhambra CA, Pasadena CA, Burbank CA, Beverly Hills CA,
Sponsor: Jonsson Comprehensive Cancer Center
Sex: Female
Age: 0+
Code: NCT06113016
Phase2, Recruiting
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
for
Prostate Adenocarcinoma,
Location: Los Angeles CA
Sponsor: Jonsson Comprehensive Cancer Center
Sex: Male
Age: 18+
Code: NCT04945642
Recruiting
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
for
Early-stage Breast Cancer,
Location: Boston MA, Wichita KS, Fullerton CA, Whittier CA,
Sponsor: Jonsson Comprehensive Cancer Center
Sex: All
Age: 18+
Code: NCT04553770
Phase2, Recruiting
New
AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer